NEWSROOM

Biotechnology

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

May 12, 2025

Preliminary net revenue increased 73% to $72.5 million for Q1 2025, compared to $41.9 million in Q1 2024 Achieved preliminary GAAP net income of $4.5 million, or $0.27 per share Reported preliminary Q1 2025 Adjusted EBITDA of $7.8 million Quarter-end cash balance of $26.7 million, up from $22.8 million as of December 31, 2024 Financial results conference call and webcast to be held on May 12, 2025 at 4:30 pm ET POMPANO BEACH, FL, May 12, 2025 - PRISM MediaWire - BioStem Technologies, Inc....

Aemetis Reports First Quarter 2025 Financial Results

Aemetis Reports First Quarter 2025 Financial Results

May 8, 2025

California Ethanol passes $2 billion cumulative revenue milestone Aemetis Biogas increased sales by 10,100 MMBtu compared with same quarter last year Sales of investment tax credits resulted in cash proceeds of $19.0 million during Q1 2025 India Biodiesel received letters of intent in April for an aggregate of $31 million of biodiesel sales to OMCs for delivery in May, June and July of 2025 CUPERTINO, Calif., May 8, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas...

Digital Utilities Ventures CEO Mark Gaalswyk Meets with QFFD in Qatar

Digital Utilities Ventures CEO Mark Gaalswyk Meets with QFFD in Qatar

May 6, 2025

Easy Environmental Solutions, Inc. Enters Strategic Talks with QFFD and African Governments to Accelerate a New Era of Regenerative Agriculture and Clean Water Infrastructure Strategic Partnership with QFFD to Transform Agriculture and Water Sustainability in Africa: Easy Environmental Solutions, Inc. (OTC: DUTV) is actively engaging with the Qatar Fund for Development (QFFD) and multiple African governments to launch scalable regenerative agriculture and clean water initiatives. This...

Aemetis Reports First Quarter 2025 Financial Results

Aemetis to Review First Quarter 2025 Financial Results on May 8, 2025

May 5, 2025

CUPERTINO, Calif., May 05, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX) announced that the company will host a conference call to review the release of its first quarter 2025 earnings report: Date: Thursday, May 8, 2025 Time: 11 am Pacific Time (PT) Live Participant Dial In (Toll Free): +1-877-545-0523 entry code 761021 Live Participant Dial In (International): +1-973-528-0016 entry code 761021 Webcast URL: https://www.webcaster4.com/Webcast/Page/2211/52416...

Aemetis Reports First Quarter 2025 Financial Results

Aemetis Biogas Completes $1.6 million of LCFS and D3 RIN Sales in April

May 1, 2025

Increasing revenues from Low Carbon Fuel Standard credits and federal D3 RINs Listened: CUPERTINO, Calif., May 01, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX), a diversified global renewable natural gas and biofuels company, announced today that the Aemetis Biogas subsidiary of the company completed $1.6 million of sales of California Low Carbon Fuel Standard (LCFS) credits and federal Renewable Fuel Standard D3 Renewable Identification Numbers (D3 RINs) during April 2025. The LCFS...

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting

May 1, 2025

Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three accepted scientific posters will feature BioStem’s advanced allograft portfolio POMPANO BEACH, Fla., May 1, 2025 - PRiSM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced its agenda for the...

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025

Apr 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 30, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will release its first quarter 2025 financial results on Monday, May 12, 2025, and will host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview of the...

Digital Utilities Ventures Announces Planned Name Change and Corporate Move as Strategic Evolution Continues

Digital Utilities Ventures Announces Planned Name Change and Corporate Move as Strategic Evolution Continues

Apr 29, 2025

Digital Utilities Ventures (OTC: DUTV) is evolving into Easy Environmental Solutions, Inc., to better reflect its focus on environmental sustainability. The company will continue to advance regenerative agriculture, clean water access, and a net carbon-neutral future through subsidiaries like Easy Energy Systems Technologies and Feed Earth Now. Under the transition from Digital Utilities Ventures (DUTV) to Easy Environmental Solutions, Inc., the company remains committed to developing...

Aemetis Reports First Quarter 2025 Financial Results

Aemetis to Benefit From EPA’s Approval of 15 Percent Ethanol Blend

Apr 29, 2025

Consumers are expected to save up to $0.20 per gallon at the pump Listened: CUPERTINO, Calif., April 29, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX), a diversified global renewable natural gas and biofuels company, announced today that the U.S. Environmental Protection Agency (EPA) issued a waiver allowing a 15 percent blend of ethanol (E15) to continue to be sold after May 1st which will benefit the company through increased demand and sales of the renewable fuel nationwide. The...

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Apr 29, 2025

Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries Listen: Broomfield, CO, April 29, 2025 – PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help...

Aemetis Reports First Quarter 2025 Financial Results

Aemetis India Begins Biodiesel Shipments to Oil Marketing Companies under $31 Million Allocation For the Next Three Months

Apr 24, 2025

Listen: CUPERTINO, Calif., April 24, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX), a diversified global renewable natural gas and biofuels company, announced the Company’s subsidiary in India, Universal Biofuels, today began shipments to fulfill multiple orders for more than 33,000 kiloliters of biodiesel from the government-owned Oil Marketing Companies (OMCs) for an aggregate of $31 million for delivery during May, June, and July. Additional OMC orders are expected throughout the...

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Apr 23, 2025

Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity Listen: PITTSBURGH, April 23, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company...

Aemetis Reports First Quarter 2025 Financial Results

Aemetis India Plant Visited by U.S. Consul General

Apr 23, 2025

Listen: CUPERTINO, Calif., April 23, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX), a diversified global renewable natural gas and biofuels company, announced the Company’s subsidiary in India, Universal Biofuels, has been working with the U.S. government to support the success of American interests in India. Aemetis owns and operates an 80 million gallon per year biodiesel production facility in Kakinada, Andhra Pradesh. The U.S. Consul General, Jennifer Larson, recently toured the...

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Apr 22, 2025

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement Listen: PITTSBURGH, April 22, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today...

Aemetis Reports First Quarter 2025 Financial Results

Aemetis India Plant Receives $31 million of Biodiesel Orders from OMCs for Delivery in Next Three Months

Apr 21, 2025

Listen: CUPERTINO, Calif., April 21, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX), a diversified global renewable natural gas and biofuels company, announced the Company’s subsidiary in India, Universal Biofuels, received multiple orders for an aggregate of $31 million for the delivery during May, June and July of more than 33,000 kiloliters of biodiesel to the three government-owned Oil Marketing Companies (OMCs). Additional OMC orders are expected throughout the year in order to...

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Apr 21, 2025

Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% Listen: BROOMFIELD, Colo., April 21, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians...

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath

Apr 15, 2025

Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic Programs NEW YORK, April 15, 2025 - PRISM MediaWire - PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. (“Opus Genetics” or the “Company”) (Nasdaq: IRD), a clinical-stage gene therapy company developing treatments for inherited retinal diseases (IRDs) and broader ophthalmic conditions. Dr. George Magrath, Chief Executive Officer of...

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

Apr 14, 2025

Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share, marking the fourth consecutive quarter of profitability Preliminary Q4 2024 Adjusted EBITDA of $11.1 Million Financial Results Conference Call and Webcast to be held on April 14, 2025 at 4:30 pm ET POMPANO BEACH, FL, April 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc....

Aemetis Reports First Quarter 2025 Financial Results

Aemetis Biogas Monthly RNG Production Increased by 55% in March

Apr 8, 2025

Sales of LCFS credits and D3 RINs completed at the end of Q1 CUPERTINO, Calif., April 08, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity renewable fuels, announced today that its production of renewable natural gas (RNG) increased 55% in March compared to February. RNG production from anaerobic dairy digesters increases during periods of warmer weather due to improved temperatures for...

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025

Apr 8, 2025

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 08, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that it will release its fourth quarter and full year 2024 financial results on Monday, April 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview...

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Apr 8, 2025

Topline Results Expected Q2 2025 Listen: PITTSBURGH, April 08, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The Phase 2a trial has now fully...

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

Apr 1, 2025

POMPANO BEACH, Fla., April 1, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces it has filed for an extension to submit its annual report for the year ended December 31, 2024 to the OTC The company is currently undergoing a mandatory Securities Exchange Commission (SEC) review process related to its Form 10 registration...

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

BioStem Announces Notice of Allowance for Two U.S. Patent Applications

Mar 31, 2025

Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of...

Digital Utilities Ventures Secures $3.4M Contract to Deploy Easy FEN™ Sustainable Agriculture Units in Africa

Digital Utilities Ventures Secures $3.4M Contract to Deploy Easy FEN™ Sustainable Agriculture Units in Africa

Mar 27, 2025

Pioneering Green Technology to Transform Food Security and Agricultural Productivity Key Highlights: Sustainable Agriculture Solution for AfricaDigital Utilities Ventures (DUTV) has secured a $3.4 million contract to deploy its patent pending Easy FEN™ modular units in Northern Africa. These advanced systems will convert 35,000 tons of biomass and food waste annually into 5.4 million gallons of Terreplenish®, an organic liquid microbial fertilizer. This initiative supports sustainable farming...

Digital Utilities Ventures Announces Planned Name Change and Corporate Move as Strategic Evolution Continues

Digital Utilities Ventures Acquires Lifestyle Dock Company, and Expands Market Reach for Easy NanoVoid™ Technology

Mar 25, 2025

Acquisition Provides Strategic East Coast Manufacturing Facility and Strengthens International Distribution Capabilities Key Highlights: Strategic Acquisition for Market Expansion: Digital Utilities Ventures (OTC: DUTV) acquires Lifestyle Dock Company (LDC), unlocking a potential $3.4 million in additional revenue and expanding the reach of its patented Easy NanoVoid™ water purification technology. This acquisition enhances DUTV’s presence in the luxury dock and marina market, introducing...

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Mar 24, 2025

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded clinical kitted product development with $50+ million in equity raises Advanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Mar 18, 2025

IRVINE, Calif., March 18, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration: Register here An archived...

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers

Feb 24, 2025

Study comparing BioStem’s proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinical efficacy to support market expansion POMPANO BEACH, FL, February 24, 2025 - PRISM MediaWire - BioStem Technologies, Inc. a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces Institutional Review Board (IRB) approval for a clinical...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025

IRVINE, Calif., Feb. 11, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to...

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Feb 11, 2025

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 - PRISM...